U.S. markets open in 8 hours 11 minutes
  • S&P Futures

    3,966.50
    +4.50 (+0.11%)
     
  • Dow Futures

    33,899.00
    +42.00 (+0.12%)
     
  • Nasdaq Futures

    11,533.00
    +8.25 (+0.07%)
     
  • Russell 2000 Futures

    1,840.80
    +3.00 (+0.16%)
     
  • Crude Oil

    78.62
    +0.42 (+0.54%)
     
  • Gold

    1,752.10
    +3.70 (+0.21%)
     
  • Silver

    21.40
    -0.04 (-0.17%)
     
  • EUR/USD

    1.0354
    +0.0019 (+0.19%)
     
  • 10-Yr Bond

    3.7480
    0.0000 (0.00%)
     
  • Vix

    21.89
    -0.32 (-1.44%)
     
  • GBP/USD

    1.1983
    +0.0033 (+0.28%)
     
  • USD/JPY

    138.3410
    -0.2930 (-0.21%)
     
  • BTC-USD

    16,859.07
    +386.58 (+2.35%)
     
  • CMC Crypto 200

    400.65
    +11.93 (+3.07%)
     
  • FTSE 100

    7,512.00
    +37.98 (+0.51%)
     
  • Nikkei 225

    27,959.43
    -68.41 (-0.24%)
     

Erasca to Present at the Morgan Stanley Global Healthcare Conference

Erasca, Inc.
Erasca, Inc.

SAN DIEGO, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Morgan Stanley Global Healthcare Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a fireside chat at 12:55 pm Eastern Time on Wednesday, September 14, 2022, at the Sheraton Hotel in New York, New York. Drs. Lim and Chacko will also participate in one-on-one investor meetings.

A live webcast of the event will be available online at https://cc.webcasts.com. An archived replay of the event will be available until December 14, 2022, following the webcast at Erasca.com/events.

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Source: Erasca, Inc.